Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2
The experimentally established mechanism targets of Cytidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | MTOR | P42345 | 2/20 | 0.97 |
| ▸ | THRB | P10828 | 1/20 | 0.97 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.97 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.97 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | GMNN | O75496 | 1/20 | 0.63 |
| ▸ | TP53 | P04637 | 1/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.63 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | HTT | P42858 | 1/20 | 0.63 |
| ▸ | RAB9A | P51151 | 1/20 | 0.63 |
| ▸ | BLM | P54132 | 1/20 | 0.63 |
| ▸ | HBB | P68871 | 1/20 | 0.63 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | CDA | P32320 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytidine SCHEMBL28578066 | 1.00 | LMNA (0.97) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL27878729 | 0.99 | LMNA (0.95) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL14644972 | 0.99 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL14853684 | 0.99 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytidine SCHEMBL8525830 | 0.99 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL23066241 | 0.99 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL172274 | 0.99 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL17993618 | 0.99 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL20546595 | 0.99 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 | |
| Cytarabine SCHEMBL329878 | 0.99 | LMNA (1.00) | LMNAMTORTHRBMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103393543-A | Method using 3D printing technology to prepare dropping pills | WEI XUEWEN | 2013-11-20 | — | — | CN | claimed |
| CN-101670100-A | Tolerogenic tumor-cell antigen-loaded dendritic cell, preparation method and application thereof | JINAN DIBO BIOTECH CO LTD | 2010-03-17 | — | — | CN | claimed |
| CN-101560496-A | Dendritic cell carried by tumor stem cell antigen and subjected to tolerance screening, preparation method and application thereof, kit and vaccine comprising dendritic cell | BEIJING CELLONIS BIOTECHNOLOGI (CN) | 2009-10-21 | — | — | CN | claimed |
| CN-101538554-A | Survivability-screened cancer stem cells, preparation method, application and kit as well as antigen composite thereof, preparation method, application and kit | BEIJING CELLONIS BIOTECHNOLOGI | 2009-09-23 | — | — | CN | claimed |
| CN-1184430-A | Interleukin in combination with pyrimidine nucleosides | HOFFMANN LA ROCHE (CH) | 1998-06-10 | — | — | CN | claimed |
| CN-1094056-A | 5 of N-oxygen carbonyl substituted '-deoxidation-5-fluorcytidines | HOFFMANN LA ROCHE (CH) | 1994-10-26 | — | — | CN | claimed |
| CN-110290787-A | For inhibiting the transfer of cancer and treating the composition of cancer | 昂科克罗斯株式会社 | 2019-09-27 | — | — | CN | disclosed |
| CN-109276722-A | Application of supramolecular framework material based on eight-membered cucurbituril in drug controlled slow release | 贵州大学 | 2019-01-29 | — | — | CN | disclosed |
| CN-108828077-A | It is a kind of while detecting the kit and its detection method of capecitabine and its metabolite and application in blood plasma | 中国人民解放军第二军医大学第二附属医院 | 2018-11-16 | — | — | CN | disclosed |
| CN-108440623-A | A kind of preparation method and products thereof of capecitabine intermediate | 重庆三圣实业股份有限公司 | 2018-08-24 | — | — | CN | disclosed |
| CN-104693256-B | The pharmaceutical applications of gemcitabine derivative, the composition containing the derivative and the derivative | 杭州源昶医药科技有限公司 | 2018-07-10 | — | — | CN | disclosed |
| CN-104744537-B | A kind of synthetic method of capecitabine | 山东诺德生物科技有限公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-104744537-B | A kind of synthetic method of capecitabine | 山东诺德生物科技有限公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-101670100-A | Tolerogenic tumor-cell antigen-loaded dendritic cell, preparation method and application thereof | JINAN DIBO BIOTECH CO LTD | 2010-03-17 | — | — | CN | disclosed |
| CN-101605892-A | The inhibition of the hepatitis C virus that mediated rnai is led | SIRNA THERAPEUTICS INC (US) | 2009-12-16 | — | — | CN | disclosed |
| CN-101560496-A | Dendritic cell carried by tumor stem cell antigen and subjected to tolerance screening, preparation method and application thereof, kit and vaccine comprising dendritic cell | BEIJING CELLONIS BIOTECHNOLOGI (CN) | 2009-10-21 | — | — | CN | disclosed |
| CN-101538554-A | Survivability-screened cancer stem cells, preparation method, application and kit as well as antigen composite thereof, preparation method, application and kit | BEIJING CELLONIS BIOTECHNOLOGI | 2009-09-23 | — | — | CN | disclosed |
| CN-101125126-A | Method for preparing medical freeze-dried powder (injection) preparation | FANZI CONG (CN) | 2008-02-20 | — | — | CN | disclosed |
| CN-1646534-A | Modified fluorinated nucleoside analogues | PHARMASSET LTD (BB) | 2005-07-27 | — | — | CN | disclosed |
| CN-1184430-A | Interleukin in combination with pyrimidine nucleosides | HOFFMANN LA ROCHE (CH) | 1998-06-10 | — | — | CN | disclosed |